Heard Isabelle, Floret Daniel
Centre national de référence des HPV, Institut Pasteur, 25-28, rue du Docteur Roux, 75724 Paris Cedex 15, France - Groupe hospitalier Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75651 Paris Cedex 13, France - Inserm U943, Université Pierre et Marie Curie, 4, place Jussieu, 75005 Paris, France.
Université Claude Bernard Lyon1, 43, boulevard du 11 novembre 1918, 69100 Villeurbanne, France.
Med Sci (Paris). 2013 Dec;29(12):1161-6. doi: 10.1051/medsci/20132912021. Epub 2013 Dec 20.
The French high council of public health has recently amended age for HPV vaccination. The paper will describe reasons that have contributed to the development of these new guidelines. Parental and adolescent acceptance of HPV vaccination is reported as well as potential barriers among medical practices. First results of immunogenicity of vaccines using alternative dosing schedules are presented. Finally, preliminary data on clinical efficacy of the quadrivalent vaccine on genital warts and cervical precancerous lesions are presented. A decrease in the prevalence of infection with genotypes included in the vaccine has now been reported in several studies. This decrease may be partly attributable to herd immunity.
